What does Andros Pharmaceuticals Co.,Ltd do?

Andros Pharmaceuticals Co.,Ltd (6917.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6917.TWO's market cap?

Andros Pharmaceuticals Co.,Ltd (6917.TWO) has a market capitalization of approximately $1.73 billion, as of August 28, 2026, based on the most recent share price and shares outstanding.

Does 6917.TWO pay a dividend?

No — Andros Pharmaceuticals Co.,Ltd (6917.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6917.TWO profitable?

Andros Pharmaceuticals Co.,Ltd (6917.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6917.TWO

Andros Pharmaceuticals Co.,Ltd

TWO·Biotechnology · Healthcare

NT$31.60NT$0.35−1.10%

Market capNT$1.73B·Market closed·Aug 28 6:52 AM UTC

Price Chart

NT$31.60−NT$0.35 (−1.10%)today

−1.19%CAGR −0.33%

Select date range

FromTo

Jan 12, 2023Jan 12, 2023 → Aug 28, 2026· 3.6 yrsAug 28, 2026

Key Metrics

6917.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$11.32M

Net Income−NT$33.35M

Net Margin−294.6%

Operating Cash Flow−NT$21.91M

Capital ExpendituresNT$114.00K

Free Cash Flow−NT$22.02M

Return on Equity−6.9%

Return on Invested Capital−7.0%

Net CashNT$318.76M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6917.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6917.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6917.TWO and 80,000+ other tickers.

About Andros Pharmaceuticals Co.,Ltd

Andros Pharmaceuticals Co., Ltd. operates as a biopharmaceutical enterprise, concentrating on the advancement of novel drug delivery platform technologies. Its development pipeline features APC101, a metered-dose, quick-drying, film-forming spray undergoing Phase IIa clinical investigation for the management of pain linked to post-herpetic neuralgia. Also in development is APC201, an innovative topical anesthetic formulation currently in Phase I/II trials for Osteoarthritis treatment, alongside an siRNA (small interfering RNA) compound functioning as an antisense oligonucleotide and DNA…

CEO: Ming-Wen Lee
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 15
Website: www.andros.com.tw

Peers

Peers Tab

4192.TWO

SynCore Biotechnology Co.,Ltd

Cap

NT$669.9M

6652.TWO

Eusol Biotech Co.,Ltd.

Cap

NT$268.5M

6876.TWO

LAUNXP Biomedical Co., Ltd

Cap

NT$834.1M

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6917.TWO

What does Andros Pharmaceuticals Co.,Ltd do?: Andros Pharmaceuticals Co.,Ltd (6917.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6917.TWO's market cap?: Andros Pharmaceuticals Co.,Ltd (6917.TWO) has a market capitalization of approximately $1.73 billion, as of August 28, 2026, based on the most recent share price and shares outstanding.
Does 6917.TWO pay a dividend?: No — Andros Pharmaceuticals Co.,Ltd (6917.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6917.TWO profitable?: Andros Pharmaceuticals Co.,Ltd (6917.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.